Figure 6.

Resibufogenin (RB) inhibits glycogen synthase kinase‐3 (GSK‐3) activity in pancreatic cancer cells. A, B, Immunoblotting determined the levels of p‐GSK‐3α, GSK‐3α, p‐GSK‐3β, and GSK‐3β (A), glycogen synthase (GS), p‐GS, and Notch1 (B) in Panc‐1 and Aspc cells incubated with 5 μmol/L RB for the indicated times. C, Dual luciferase assay verified the TOPFlash and FOPFlash activity in RB‐treated Panc‐1 and Aspc cells. D, Viability in Panc‐1 cells transfected with GSK‐3β WT, S9A, and K85A following RB (5 μmol/L) treatment for 24 hours was measured by MTT. *P < .05, **P < .005; ^# P < .05